Intestinal microsporidiosis in French heart transplant recipients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Researchers will perform a national retrospective review of medical records to collect epidemiological, biological, clinical, and treatment data on intestinal microsporidiosis in heart transplant recipients. The study will include patients diagnosed in metropolitan France and overseas territories before December 31, 2024, unless they oppose participation. No interventions are planned; data will be extracted from existing records at participating centers, led by CHU Gabriel Montpied (Clermont-Ferrand). The goal is to characterize frequency, presentation, diagnostic methods, and treatment outcomes in this population.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* heart transplant patients diagnosed with intestinal microsporidiosis
* diagnosis made before December 31, 2024 in France (metropolitan France and overseas territories)

Exclusion Criteria:

-patient opposition

Where it's running

• CHU Gabriel Montpied
  Clermont-Ferrand, France Recruiting

Study contacts

• Study coordinator: Lise Laclautre
• Email: promo_interne_drci@chu-clermontferrand.fr
• Phone: +33473754963

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Letermovir versus valganciclovir to prevent CMV after heart transplant

  This trial will test whether letermovir or valganciclovir better prevents CMV viremia in adults at moderate-to-high CMV risk after a heart transplant.

  Recruiting at 2 sites Phase 2/3 Columbia University · New York, New York and 1 other locations · NCT07079735

• Evaluating infection management in children with heart-assist devices

  This study looks at how to better manage infections in children using heart-assist devices to help improve their health while they wait for a heart transplant.

  Recruiting Claude Bernard University · Lyon · NCT06464016

• Levothyroxine for heart transplant recipients

  This study is testing if taking levothyroxine can help heart transplant recipients live longer compared to those who receive a placebo.

  Recruiting Phase 1 University of California, San Francisco · San Francisco, California · NCT06428097

• MMR vaccination for children after heart transplant

  We will give the MMR (measles, mumps, rubella) vaccine to children and teens who had a heart transplant to see if it's safe and helps them make protective antibodies.

  Recruiting Phase 4 Children's Mercy Hospital Kansas City · Kansas City, Missouri · NCT07195032

• Non-invasive test to predict early heart rejection in pediatric transplant patients

  This study tests non-invasive heart tests like cardiac MRI and blood markers to see if they can detect rejection in kids after heart transplant, potentially reducing the need for invasive biopsies.

  Recruiting at 22 sites Vanderbilt University Medical Center · Little Rock, Arkansas and 21 other locations · NCT07770659

• Non-intubated anesthesia for adult heart transplantation

  This trial tests whether keeping patients breathing on their own with a supraglottic airway during heart transplantation leads to fewer complications and faster recovery compared with standard intubated anesthesia.

  Recruiting The First Affiliated Hospital of Guangzhou Medical University · Guangzhou, Guangdong · NCT07758894

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.